| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2796695 | Diabetes Research and Clinical Practice | 2013 | 5 Pages |
Abstract
Dipeptidyl peptidase-4 inhibitors (DPP-4Is) inhibit the inactivation of incretin hormones while also affecting the immune system, since CD26/DPP-4 is involved in immune regulation. The current study shows that the use of DPP-4Is as therapy for type 2 diabetes patients may induce joint symptoms with decrease in plasma SDF-1α level.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Tatsuhiko Saito, Kei Ohnuma, Hiroshi Suzuki, Nam H. Dang, Ryou Hatano, Hiroki Ninomiya, Chikao Morimoto,